Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
IRF2, which binds to chromatin both independently and in cooperation w/ IRF1 and IRF4, is an essential transcription factor w/ pathogenic and prognostic impact in myeloma, and suppresses necroptosis and promotes cell migration.”
Title: IRF2 is an Essential Transcription Factor with Pathogenic and Prognostic Impact in Multiple Myeloma
Authors: Nahia Gómez-Echarte, Arantxa Carrasco-Leon, Alba Maiques-Diaz, Naroa Barrena, Estibaliz Miranda, Leire Garate, Ane Amundarain, Patxi San Martín-Úriz, Stella Charalampopoulou, Luis Valcárcel, Beñat Ariceta, Paula Rodriguez-Marquez, Juan Roberto Rodriguez-Madoz, Kazuya Ishiguro, Francisco Planes, Paula Rodriguez-Otero, Constantine Mitsiades, José-Ignacio Martín-Subero, Edurne San-José Enériz, Felipe Prosper, Xabier Agirre
You can read the Full Article on Blood.
You can find other articles featuring Robert Orlowski on OncoDaily.